Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Gilead Sciences Earnings Preview: What to Expect

January 19, 2026 at 08:15 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company headquartered in Foster City, California, known for discovering, developing, and commercializing innovative medicines that address serious unmet medical needs in areas such as HIV/AIDS, viral hepatitis, COVID-19, oncology, and inflammation. Gilead Sciences has a market cap of around $155 billion, reflecting its position as a significant player in the healthcare and biotechnology sectors.

The company is set to announce its fiscal Q4 earnings results soon. Ahead of the event, analysts expect GILD to report a profit of $1.86 per share, down 2.1% from $1.90 per share in the year-ago quarter. The company surpassed Wall Street’s bottom-line estimates in three of the past four quarters and missed on another occasion.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For fiscal 2025, analysts expect GILD to report EPS of $8.14, up 76.2% from $4.62 in fiscal 2024. Also, its EPS is forecasted to rise by 4.8% in fiscal 2026, reaching $8.53.

GILD has surged 36.3% over the past year, outpacing the S&P 500’s ($SPX) 16.9% gains and the State Street Health Care Select Sector SPDR ETF’s (XLV) 10.4% return over the same time frame.

Gilead’s stock has been rising as investors are encouraged by new product approvals and pipeline progress, notably the boost from the HIV prevention drug Yeztugo and solid HIV franchise performance. The FDA approval and commercial rollout of the new HIV prevention product, the twice-yearly injectable Yeztugo, will expand the company’s potential market and boost investor confidence.

The consensus opinion on GILD is bullish, with an overall “Strong Buy” rating. Among the 30 analysts covering the stock, 22 advise a “Strong Buy,” two recommend a “Moderate Buy,” and six suggest “Hold.” GILD’s average analyst price target is $135.67, indicating a potential upside of 8.6% from the current price levels.

On the date of publication, Subhasree Kar did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article